fr
Article scientifique
Accès libre
Anglais

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Publié dansAnnals of the rheumatic diseases, vol. 72, no. 4, p. 482-492
Date de publication2013
Résumé

Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.

Mots-clés
  • Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects
  • Antirheumatic Agents/administration & dosage/adverse effects
  • Arthritis, Rheumatoid/drug therapy/immunology
  • Drug Monitoring/methods
  • Humans
  • Inflammation/drug therapy/immunology
  • Interleukin-6/antagonists & inhibitors
  • Receptors, Interleukin-6/antagonists & inhibitors
Citation (format ISO)
SMOLEN, Josef S et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. In: Annals of the rheumatic diseases, 2013, vol. 72, n° 4, p. 482–492. doi: 10.1136/annrheumdis-2012-202469
Fichiers principaux (1)
Article (Published version)
accessLevelPublic
Identifiants
ISSN du journal0003-4967
539vues
331téléchargements

Informations techniques

Création22.01.2015 16:20:00
Première validation22.01.2015 16:20:00
Heure de mise à jour14.03.2023 22:45:06
Changement de statut14.03.2023 22:45:05
Dernière indexation16.01.2024 16:25:38
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack